Oral immune-related adverse events associated with PD-1 inhibitor therapy: A case series.
Muhammad Ali ShazibSook-Bin WooHervé SroussiIngrid CarvoNathaniel TreisterArwa M FaragJonathan SchoenfeldRobert HaddadNicole LeBoeufAlessandro VillaPublished in: Oral diseases (2020)
Patients receiving PD-1 inhibitors may develop oral irAEs characterized by lichenoid lesions, ulcers, or EM. Topical and systemic steroids appear to be effective in managing oral lesions although the severity of irAEs may necessitate PD-1 inhibitor therapy dose modification.